JOHNSON & JOHNSON is 285.5x more valuable than Aurinia Pharmaceuticals Inc. by market capitalization ($573.98 B vs $2.01 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AUPH | JNJ |
|---|---|---|
| Market cap | $2.01 B | $573.98 B |
| US-listed rank | #2095 | #20 |
| Revenue (latest FY) | $283.06M | $94.19B |
| Net income (latest FY) | $287.20M | $26.80B |
| Net margin | 101.5% | 28.5% |
| P/E (trailing FY) | 7.0 | 21.4 |
| SEC filings | 595 | 984 |
JOHNSON & JOHNSON is 285.5x more valuable than Aurinia Pharmaceuticals Inc. by market capitalization ($573.98 B vs $2.01 B).
In their latest fiscal years, Aurinia Pharmaceuticals Inc. reported $283.06M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Aurinia Pharmaceuticals Inc. and JOHNSON & JOHNSON, or browse the full rankings.